RESUMEN
The study showed that ulcer disease in patients with metabolic syndrome is characterized by painless clinical course, bowel disorders in the form of constipation, enhanced appetite, unmotivated requirement for hypoglycemic therapy predisposition to complications along with activation of the inflammatory process in duodenal mucosa, high H. pylori count. The data obtained were used to develop the age-specific strategy for the treatment of elderly patients with duodenal ulcer and concomitant metabolic syndrome.
Asunto(s)
Comorbilidad , Úlcera Duodenal/fisiopatología , Síndrome Metabólico/fisiopatología , Polifarmacia , Factores de Edad , Anciano , Úlcera Duodenal/tratamiento farmacológico , Úlcera Duodenal/epidemiología , Humanos , Masculino , Síndrome Metabólico/tratamiento farmacológico , Síndrome Metabólico/epidemiología , Persona de Mediana EdadRESUMEN
Effects of pirebedil used to prevent falls in elderly patients with metabolic syndrome are discussed. A prospective controlled study showed that therapy with pirebedil significantly decreases the frequency of falls, reduces severity of pro-inflammatory and pro-oxidative activities, improves cognitive abilities. Prevention of falls by virtue of improved cognitive abilities is a new clinical effect of pirebedil and gives reason to recommend it for the treatment of geriatric patients with metabolic syndrome.